In randomized trials, the effect of vitamin D supplementation on blood pressure has been equivocal, while most prospective cohort studies have shown that the risk of incident hypertension is lower in people with higher levels of 25-hydroxyvitamin D (25(OH)D). The authors examined the association between levels of 25(OH)D and changes in blood pressure and incident hypertension in 4,863 postmenopausal women recruited into the Women's Health Initiative between 1993 and 1998. Over 7 years, there were no significant differences in the adjusted mean change in systolic or diastolic blood pressure by quartile of 25(OH)D. The covariate-adjusted risk of incident hypertension was slightly lower in the upper 3 quartiles of 25(OH)D compared with the lowest quartile, but this was statistically significant only in the third quartile (hazard ratio ¼ 0.67, 95% confidence interval: 0.46, 0.96). There was no significant linear or nonlinear trend in the risk of incident hypertension by untransformed or log-transformed continuous values of 25(OH)D. In postmenopausal women in this study, serum levels of 25(OH)D were not related to changes in blood pressure, and evidence for an association with lower risk of incident hypertension was weak. Although some animal studies suggest that vitamin D supplementation may lower blood pressure (1, 2), the results of randomized trials in humans have been equivocal (3-5). The largest of these, the Women's Health Initiative randomized trial of dietary supplementation with calcium plus vitamin D (CaD), included long-term follow-up of over 36,000 women (6). Over a median follow-up time of 7 years, there was no significant difference in the mean change over time in systolic blood pressure (SBP) or diastolic blood pressure (DBP), or in incident hypertension between the randomized active and placebo treatment groups, either overall or in the subgroups with low intake of vitamin D or low serum levels of vitamin D (7). However, the lack of effect on blood pressure in the Women's Health Initiative CaD trial may have reflected an insufficient contrast in supplemental intake between the intervention and control groups. This could have resulted from too low a dose of vitamin D (400 IU/day) or nonadherence to study medication in the intervention group and from use of supplemental vitamin D in the control group.
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In randomized trials, the effect of vitamin D supplementation on blood pressure has been equivocal, while most prospective cohort studies have shown that the risk of incident hypertension is lower in people with higher levels of 25-hydroxyvitamin D (25(OH)D). The authors examined the association between levels of 25(OH)D and changes in blood pressure and incident hypertension in 4,863 postmenopausal women recruited into the Women's Health Initiative between 1993 and 1998. Over 7 years, there were no significant differences in the adjusted mean change in systolic or diastolic blood pressure by quartile of 25(OH)D. The covariate-adjusted risk of incident hypertension was slightly lower in the upper 3 quartiles of 25(OH)D compared with the lowest quartile, but this was statistically significant only in the third quartile (hazard ratio ¼ 0.67, 95% confidence interval: 0.46, 0.96). There was no significant linear or nonlinear trend in the risk of incident hypertension by untransformed or log-transformed continuous values of 25(OH)D. In postmenopausal women in this study, serum levels of 25(OH)D were not related to changes in blood pressure, and evidence for an association with lower risk of incident hypertension was weak. Although some animal studies suggest that vitamin D supplementation may lower blood pressure (1, 2) , the results of randomized trials in humans have been equivocal (3) (4) (5) . The largest of these, the Women's Health Initiative randomized trial of dietary supplementation with calcium plus vitamin D (CaD), included long-term follow-up of over 36,000 women (6) . Over a median follow-up time of 7 years, there was no significant difference in the mean change over time in systolic blood pressure (SBP) or diastolic blood pressure (DBP), or in incident hypertension between the randomized active and placebo treatment groups, either overall or in the subgroups with low intake of vitamin D or low serum levels of vitamin D (7) . However, the lack of effect on blood pressure in the Women's Health Initiative CaD trial may have reflected an insufficient contrast in supplemental intake between the intervention and control groups. This could have resulted from too low a dose of vitamin D (400 IU/day) or nonadherence to study medication in the intervention group and from use of supplemental vitamin D in the control group.
Despite the inconclusive evidence from clinical trials, it is important to consider data from observational studies, which may include more representative populations with wider variations in vitamin D intake and serum levels. Although most of the biologic action including the possible blood pressure effects is likely mediated through 1,25-dihyroxyvitamin D 3 , 25-hydroxyvitamin D 3 (25(OH)D) is generally considered the best biomarker for assessing vitamin D status. Several prospective studies have suggested that the risk of incident hypertension is lower among men and women with higher levels of 25(OH)D. In a study of male and female health professionals, the relative risk of self-reported incident hypertension with 25(OH)D levels of <30 ng/mL (or <75 nmol/L) was 3.2 (95% confidence interval (CI): 1.4, 7.3) compared with individuals with 25(OH)D levels of !30 ng/mL, after adjustment for age, race, menopausal status, body mass index, and physical activity (8) . A case-control study in another cohort of nurses aged 32-52 years similarly found an elevated adjusted risk of self-reported incident hypertension among women with 25(OH)D blood levels of <30 ng/mL (relative risk ¼ 1.5, 95% CI: 1.1, 2.0) (9) . Another population-based study among women aged 22-44 years at baseline found that a low level of 25(OH)D predicted a 3.0-fold risk (95% CI: 1.1, 8.7) of incident systolic hypertension 13 years later, although there was no difference in the rate of change in blood pressure over the same time period (10) . However, in contrast to these studies, a recent Norwegian study did not find an association of 25(OH)D levels with future hypertension or an increase in measured blood pressure (11) . Thus, evidence from prospective studies regarding the association of 25(OH)D levels with the development of high blood pressure is also mixed.
The Women's Health Initiative CaD trial data set includes several thousand women aged 50-79 years with baseline measurements of serum 25(OH)D who had long-term followup including annual blood pressure measurements by trained technicians, semiannual determinations of self-reported incident hypertension treatment, and periodic medication inventories. Because the trial results did not reveal any effect of the supplement intervention on hypertension or blood pressure, we used these data in an observational study to prospectively examine the association of baseline levels of 25(OH)D and changes in blood pressure and incident hypertension in postmenopausal women enrolled in the Women's Health Initiative.
MATERIALS AND METHODS
Between 1993 and 1998, postmenopausal women aged 50-79 years were recruited at 40 US clinical centers into the Women's Health Initiative randomized trials assessing the risks and benefits of hormone therapy and dietary modification (12, 13) . Participants enrolled in one or both trials were further invited to join the CaD trial at their first (n ¼ 33,070) or second (n ¼ 3,212) annual follow-up visit. Baseline serum 25(OH)D levels were measured in 4,867 participants in 2 nested case-control studies in the CaD trial (7, (14) (15) (16) . Cases in the first study had incident hip, spine, arm, or wrist fractures (n ¼ 1,510) or colorectal cancer (n ¼ 331) and in the second study had incident invasive breast cancer (n ¼ 1,081). Controls were individually matched to case participants according to age, clinical center, race or ethnic group, and month of blood draw and were respectively free of fracture, colorectal cancer, or breast cancer for the duration of the study. We excluded 4 participants whose blood draw date occurred after the first annual follow-up visit, for a final sample of 4,863 women for this analysis.
Blood specimens were obtained after an overnight fast at the randomization visit, processed, frozen at À70°C, and stored according to a standard protocol. The specimens were analyzed with the DiaSorin Liaison chemiluminescent immunoassay system at DiaSorin headquarters (Stillwater, Minnesota) in 2 batches with blinded control runs at periodic intervals (coefficient of variation, 11.8%). The fracture and colorectal cancer cases and controls were analyzed in 2005, and the breast cancer cases and controls were analyzed in 2007. Case and control samples were measured in tandem in random order.
Blood pressure was measured by certified staff using standardized procedures and instruments, in the right arm, with a conventional mercury sphygmomanometer and an appropriately sized cuff, after the participant was seated and resting for 5 minutes (17) . Two measurements, obtained at least 30 seconds apart, were performed at the enrollment visit and at each subsequent annual visit. The average of the 2 measurements was used for analyses.
At enrollment, participants were asked whether they had been diagnosed by a physician with high blood pressure or hypertension and if they were taking medications for hypertension. Then, at each semiannual contact, participants were asked, ''Since the date given on the front of this form, has a doctor prescribed any of the following pills or treatments?'' The choices included ''pills for hypertension.'' Medication inventories were conducted at enrollment and at the first, third, sixth, and ninth annual visits. The product or generic name of the medications on the label was entered into the study database and matched to the corresponding item in a pharmacy database (Master Drug Data Base (MDDB); MediSpan (Wolters Kluwer Health), Indianapolis, Indiana). Drugs from the following classes were considered to be antihypertensive agents: angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, b-blockers, calcium channel blockers, diuretics, centrally acting antihypertensive agents, vasodilators, and combinations of these medications. At enrollment in the Women's Health Initiative study, 94% of women with self-reported hypertension treatment had an antihypertensive agent in the baseline drug inventory, and 79% with incident self-reported hypertension treatment during the first year of the trial brought an antihypertensive medication to the year 1 drug inventory.
Demographic variables and health history data were selfreported at the Women's Health Initiative baseline. Dietary data were collected by using a validated food frequency questionnaire (17) . Total calcium and vitamin D intakes included both dietary and supplement sources determined from the medication and supplement inventory. Metabolic equivalent task scores were calculated from the frequency and duration of recreational physical activity (18) .
Serum vitamin D quartiles (<34.4, 34.4-47.6, 47.7-64.6, and !64.7 nmol/L) were created on the basis of the levels in the combined control groups. To convert nmol/L to ng/mL, divide by 2.496. We also conducted analyses using categories of serum 25(OH)D that are commonly used in clinical practice (<25, 25-<50, 50-<75, and !75 nmol/L). Blood pressure change was determined by using annual blood pressure measurements collected through 7 years of follow-up minus the blood pressure at the CaD randomization visit. Associations between baseline serum 25(OH)D level and change in systolic or diastolic pressure over time were analyzed by using generalized estimating equations. All participants with at least one blood pressure change measurement were included in the repeated measures models. Correlations among responses within a participant were specified as unstructured.
Because the sample of participants with serum 25(OH)D measures was not a random sample of the cohort, probability sampling weights were incorporated into the models to approximate the analysis that would have occurred if serum 25(OH)D data had been available for the whole cohort. Weights were estimated as the inverse of the sampling fractions from strata defined by age in decades, race/ethnicity (white, black, Hispanic, other), and case status in the prior case-control studies. Because of this weighting, the results were more heavily influenced by the controls than the cases. In sensitivity analyses, we also examined the results in controls only. Plots of longitudinal data were based on fitted means from these models where both serum 25(OH)D and time were modeled as class variables and the association of serum 25(OH)D with blood pressure change was allowed to vary over time. We also evaluated change in systolic or diastolic pressure, under assumptions that the associations with 25(OH)D were constant over time. Because generalized estimating equation models are valid when data are missing completely at random but not necessarily under other missing data mechanisms, we conducted sensitivity analyses that included only women with blood pressure measured at all 7 years of follow-up.
To control for potential confounding, we adjusted all models for the case-control matching factors: age at initial screening (continuous), race/ethnicity, clinical center of blood draw, and month of blood draw. Additional models were adjusted for CaD trial assignment to intervention or placebo, education (less than high school, high school degree/general education diploma, education beyond high school), alcohol intake (nondrinker, <1 drink/day, !1 drinks/day), smoking (never smoked, past smoker, current smoker), body mass index at CaD enrollment, baseline physical activity (metabolic equivalent task (MET) hours/week), blood pressure at enrollment (normotensive, prehypertensive, hypertensive), antihypertensive medication use at time of CaD enrollment, and history of cardiovascular disease or diabetes at baseline. Body mass index, smoking status, and antihypertensive medication use were updated at each annual visit in the models as time-varying variables. Dietary and supplemental vitamin D intake were considered as covariates in a separate model, because intake could be in the causal pathway as a determinant of serum 25(OH)D levels. Similarly, because the baseline 25(OH)D level could be causally related to baseline blood pressure, we conducted additional analyses that did not adjust for baseline blood pressure.
The association of 25(OH)D level with incident hypertension was examined by using Cox proportional hazards models to estimate adjusted hazard ratios and 95% confidence intervals. The time in days from CaD enrollment was used as the basic time variable. Incident hypertension was defined as the first self-report of medication prescribed for hypertension or any blood pressure of !140/90 mm Hg during 7 years of follow-up among 2,153 women who did not have hypertension at CaD enrollment (no self-report of hypertension treatment, no antihypertensive medications in inventory, and blood pressure at all visits of <140/90 mm Hg prior to randomization). Follow-up time was censored for women not developing hypertension at the time of the last documented follow-up contact, death, or September 15, 2005 (whichever came first). As in the longitudinal analyses of blood pressure change, the inverse of estimated sampling probabilities was used to The association of 25(OH)D and incident hypertension within specific subgroups was examined by extending the models to include interaction terms between the categorical 25(OH)D variable and each factor of interest. Covariates in the incident hypertension models differed slightly from those described above because of the exclusion of women with hypertension at CaD enrollment. Therefore, blood pressure at enrollment included only normotensive and prehypertensive categories. Because none of the participants in analyses were taking antihypertensive medication at enrollment and the self-report of initiating antihypertensive treatment during follow-up was part of the incident hypertension outcome, these were not included as covariates. All P values presented are 2 sided. Data analyses were performed by using STATA, version 10, software (StataCorp LP, College Station, Texas).
RESULTS
At baseline, the mean age was 66 (standard deviation, 7) years, the mean blood pressure was 127/74 mm Hg, and 49% of the participants had hypertension. In unadjusted analyses by serum 25(OH)D quartiles, low serum levels were associated with the following baseline characteristics: older age, minority race/ethnicity, lower educational level, blood draw during winter or spring, history of cardiovascular disease or diabetes, higher blood pressure, hypertension, higher body mass index, lower physical activity, current smoking, lower alcohol intake, lower calcium intake, and lower vitamin D intake ( Table 1) . Among the 4,863 participants, by the end of the CaD study, 318 (6.5%) had died, 54 withdrew, and an additional 18 women were considered lost to follow-up.
Over a median follow-up time of 7 years and after adjustment for potential confounders, there were no significant differences in the mean change over time in SBP or DBP by quartile of serum 25(OH)D (Figure 1) . Although SBP and DBP declined over time, the change in SBP or DBP by 25(OH)D category was not significantly different at any point in time (SBP, P interaction ¼ 0.21; DBP, P interaction ¼ 0.73). There were also no differences in SBP or DBP by quartile of vitamin D in stratified analysis of women with hypertension (not shown) and without hypertension (Figure 2) . The results were nearly identical when using clinical cutpoints to define the serum 25(OH)D categories. Additional adjustment for vitamin D intake did not materially change the results, nor did not adjusting for baseline blood pressure. The results were also similar in analyses of controls only and in women with complete data at all 7 follow-up visits. No significant interaction of 25(OH)D quartile with non-white race was observed.
In the minimally adjusted model 1 (Table 2) , the risk of incident hypertension was slightly lower in the upper 3 quartiles of 25(OH)D compared with the lowest quartile, but this was statistically significant only in the third quartile (hazard ratio ¼ 0.70, 95% CI: 0.51, 0.96). Results were similar in models adjusted for additional potential confounders (Table 2) and when baseline blood pressure was not included as a covariate (data not shown). No significant interactions were observed with race, body mass index, smoking, or level of baseline blood pressure. In the models using clinical categories of serum 25(OH)D, compared with a level of <25 nmol/L, none of the higher categories had a significantly lower risk of incident hypertension. These results are consistent with findings from another recent Norwegian prospective study that included a broad age spectrum of men and women (11) . Several other prospective studies did find that low levels of 25(OH)D were predictive of self-reported incident hypertension in health professionals, but these studies did not include measured blood pressure (8, 9) .
A recent meta-analysis of the effect of vitamin D on blood pressure included 11 trials of a-calcidiol, cholecalciferol, calcium plus cholecalciferol, ergocalciferol, and ultraviolet B in diverse study populations of a total of 270 subjects, most of whom had blood pressure in the hypertensive range (3). The studies ranged in duration from 5 weeks to 12 months, and the Women's Health Initiative CaD trial was not included. Overall, there were no differences in SBP, but a small difference in DBP was observed with treatment (À3.1 mm Hg, 95% CI: À5.5, À0.6). Subgroup analyses suggested less effect in trials of activated vitamin D and in trials with normotensive subjects. Two trials published after this meta-analysis (one in 165 healthy overweight German men and women (23) and another in 438 overweight and obese Norwegian men and women (5)) did not find any effects on blood pressure of 12 months of supplementation with substantial doses of cholecalciferol (3,332 IU/day and 40,000 IU/week, respectively).
Elegant experiments in vitamin D receptor knockout mice have shown increased activation of the renin-angiotensinaldosterone system that can be reversed by administration of A) (4, (26) . The results from the present Women's Health Initiative observational study in postmenopausal women may differ from results in younger women, who were the majority of the participants in some of the previous prospective cohort studies. Another potential reason that our results might differ from other studies is because of rigorous adjustment for potential confounders, but the results of our study changed little when additional covariates were added to models adjusted for age, race, clinical center, and month of blood draw. Probably a more important factor was the rigor with which we measured blood pressure and adjusted for commencement of antihypertensive treatment over time. Although incident hypertension was based in part upon self-reports of beginning new antihypertensive therapy, we have shown that these self-reports were quite reliable on the basis of comparisons with inventories of actual medications being taken. A limitation is that we did not have information about subsequent addition of new antihypertensive drugs or dosage adjustment. Another limitation is that 25(OH)D was measured only once; lack of precision in determining 25(OH)D levels could have hampered detecting true associations. Finally, we acknowledge that our serum 25(OH)D measurements were taken from case-control studies designed to study conditions other than hypertension, and that statistical adjustment was required to account for this design. However, we did not observe different results without statistical adjustment or in controls.
We conclude that, in generally healthy postmenopausal women, serum levels of 25(OH)D are not related to changes in blood pressure or to incident hypertension. Although the evidence that vitamin D has an effect on cardiovascular disease and mortality is inconsistent and controversial, it has generated intense interest (27) (28) (29) (30) (31) (32) (33) . A large planned placebocontrolled trial, the VITamin D and OmegA-3 TriaL (VITAL), should provide more information about the effect of vitamin D supplementation on a variety of outcomes, including hypertension.
